‘Musseling Up’ clinical trial aims to provide facts about shellfish benefits
New Zealand’s iconic Greenshell™ mussels (GSM) are world-famous for their delicious taste, but now a clinical trial is
about to get underway that will provide facts about the key active components in the shellfish.
Cawthron Institute, Christchurch Clinical Studies Trust (CCST), and Sanford Limited have joined forces to identify and
validate the health benefits of Greenshell™ mussels, in particular looking at potential anti-inflammatory qualities,
improved joint and bone health, and increased mobility.
The research programme is funded by the Government’s High Value Nutrition (HVN) National Science Challenge and co-funded
by Sanford Limited, New Zealand’s biggest producer and exporter of Greenshell™ mussels. Sanford is a long-established
seafood company devoted entirely to sustainable harvesting, farming, processing, storage and marketing of quality
seafood and aquaculture products.
Cawthron Marine Lipid Chemist and programme leader Dr Matt Miller says the project’s aim is to add even more value to
this gourmet delicacy by fully understanding and proving its health benefits.
New Zealand’s Greenshell™ mussels attract $292 million in export earnings each year because of their highly desirable
taste and plate appeal.
While Greenshell™ mussels are primarily promoted as a whole product, this iconic delicacy has many hidden health
benefits that need to be better understood.
Dr Miller says one thing scientists do not know is what happens to the key active ingredients from Greenshell™ mussels
after they’ve been eaten.
The clinical trial will generate scientific evidence about the health benefits of Greenshell™ mussels and assist the
industry to identify and develop the best Greenshell™ mussel-based functional food products that will appeal to the
emerging market of health-conscious consumers.
The clinical trial, which starts on 14 August, looks at the digestibility of the active components in Greenshell™
mussels.
Conducted in collaboration with the Christchurch Clinical Studies Trust (CCST), a dedicated unit with a long history in
clinical trials, the trial will feed eight healthy male subjects a soup that will contain either mussel oil, mussel
powder, a mussel powder derived food ingredient, or cooked whole mussels.
Dr Miller says the trial will help scientists understand what happens to the active components after digestion, how much
gets into the blood, and how much is therefore bioavailable to the consumer.
Bioavailability will be assessed in a variety of food and ingredient formats which will be used to confirm absorption of
key active ingredients from Greenshell™ mussels and enable food design for health claims.
Dr Miller says earlier tests using models has shown some “really interesting” results around joint health and mobility.
General Manager of Innovation at Sanford, Andrew Stanley says “we’re really excited to be part of this project. We have
had so much anecdotal evidence over the years about the power of New Zealand Greenshell™ mussels and it will be
excellent to be able to explore how these benefits are actually best delivered.”
Dr Miller says the long-term aim of the research is to assist the transition of Greenshell™ mussels from a market
concentrated on relatively low price commodity protein products to a market position based on high-value nutrition and
health products.
“The project aims to grow Greenshell™ mussels exports, and future proof New Zealand’s important Greenshell™ mussels
industry.”
ENDS